As early as 1906, Dr. Aloysius Alzheimer found that erythropoiesis formed by β-amyloid (Aβ) deposition and the highly-phosphorylated Tau protein-induced neurofibrillary tangles were the brain pathological features of Alzheimer's disease (AD). Since that time, almost all of the disease-modifying new drugs under development are targeting Aβ or Tau protein.
In 2008, the author's article "Treatment Progress Changes the Course of Alzheimer's Disease" published in the Shanghai Archives of Psychiatry, highlighted that at that time numerous drugs based on the AD pathophysiological hypothesis were in phase II of clinical trials. [1] However, there has still been no fundamental breakthrough in the treatment of AD from these new drugs in trial.
Studies on the β-amyloid monoclonal antibody did not have any success in phase III trials. [2, 3] On November 23, 2016, Eli Lily Company reported their new drug Solanezumab, an β-amyloid monoclonal antibody, had finished phase III of its clinical trial. Despite this medication achieving an 11% reduction in cognitive decline among patients with AD when compared to those in the placebo group, there was no significant difference in the ADAS-Cog scores (the primary measurement tool used in this study). Prior to this, studies of the β-amyloid monoclonal antibody Bapineuzumab [2] (Pfizer Company and Johnson& Johnson Pharmaceuticals), and Gantenerumab [4] (Roche Pharmaceutical) were already determined to have been unsuccessful or terminated during phase III of their trial. Perhaps the failure of Solanezumab is related to its single targeting of the soluble monomer β-amyloid and its inability to clear β-amyloid patches that have already gathered. Despite Gantenerumab as a fully humanized monoclonal antibody technically having the function of clearing β-amyloid plaques gathered in the brain of those with AD, however during its mid-term analysis of the phase III study no significant effect was shown, finally leading to announcement of study termination in 2014. An argument against β-amyloid antibody is that using β-amyloid antibody is too late in the course of AD, making it impossible to achieve a good outcome.
The timing of medical interventions should be moved up to the prodromal period, mild cognitive impairment stage or earlier. [5] Another paradox is that the dosage of antibody in the brain is closely related to clinical effect but also the risk of adverse effect. By simply increasing the dosage, the absolute concentration does increase, but also activates the microglia cells in the brain and causes adverse effects. To address these questions, the Biogen Company recently reported that their new drug aducanumab could decrease the concentration of β-amyloid in patients with AD in a time and dose dependent manner (as shown in a phase I clinical trial). [6] Aducanumab is an antibody isolated from targeted senile plaques in the B-cells of healthy elders, it can increase the concentration of the drug in the brain without causing serious adverse reactions. At present, Biogen is conducting two Phase III clinical trials of Aducanumab, and the results are expected to be published in 2018. Roche and Genentech are designing their new antibodies Crenezumab based on the IgG4, which activates microglia cells less, and reduces the incidence of adverse reactions. Less adverse effects allow for a higher available dosage in clinical trials, opening up the possibility of achieving better results.
New drugs based on BACE1 (beta-site amyloid precursor protein-cleaving enzyme 1) and gammasecretase have also not shown success. In 2013, Eli Lily's announced its gamma-secretase inhibitor Semagacestat had failed after phase III of the clinical trial. On 14 February 2017, Merck Company also terminated a phase III clinical trial of their BACE1 inhibitor Verubecestat, when it was considered extremely unlikely that it would obtain a clinically significant result. The reason for this failure is also related to the timing of intervention selected. By the time a diagnosis of mild AD is given it may be too late in the course of illness to successfully utilize an intervention which targets β-amyloid production.
Research into drugs targeting Tau protein is also facing difficulties. [7] Recently, the TauRx Company reported that the phase III trial of their new drug LMTM (an amethylthionine chloride derivation which was thought to be able to inhibit the generation of neurofibrillary tangles through Tau) was unsuccessful. [8] Phase III trials will begin this year. Mannose oligosaccharide dicarboxylic acid is an oligosaccharide extract obtained from seaweed, and was developed by China Oceanic University and the CAS Shanghai Institute of Materia Medica. In an experiment it was shown to inhibit neurotoxicity for β-amyloid. Its phase III trial using a 900mg daily dose is ongoing, with results to be released in 2018.
In conclusion, the results of clinical trials of these drugs have made us more aware of the complexity of the pathogenesis of Alzheimer's disease. Although the hypothesis of amyloid and Tau protein is currently the mainstream explanation for AD onset, [9] it is possible that this is only the tip of the iceberg when it comes to the pathogenesis of AD. A series of novel approaches and innovations are currently emerging such as neurotransmitter based treatments, new drug delivery systems/ methods, cholesterol and lipid treatments, neurotrophic factor treatments, metal-protein chelation therapies, insulin/metabolic treatments, stem cells treatment, gene therapies, neuro-transplantation and neurosurgery treatments. Today, research on the genetic regulation of BACE1 mRNA is underway, [10] hoping to find a new target for AD intervention. We also expect to soon see new drugs which are based outside of the amyloid and Tau hypothesis.
• 239 • 
